Sanofi signals a big interest in oncology as it adds a cancer R&D star to the board

It’s not common for Big Pharma to put the CMO of a small biotech company on the board. But that’s exactly what Sanofi chairman Serge Weinberg is doing, and it says a lot about the future direction the pharma giant is taking as Paul Hudson continues to build out what he hopes will be a far more exciting pipeline.